Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.

Biotech and drug-innovation themes continue to dominate markets—from AI-driven drug discovery to blockbuster obesity treatments—and a new ETF filing suggests asset managers want a piece of that ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying off. First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) has surged ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...